Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3Carcinoma, Neuroendocrine 1Advanced Solid Tumors 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Immune Checkpoint Inhibitors 30Capecitabine 30Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × TLC 388 × Clear all
NCT02267213 2019-02-26

Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Taiwan Liposome Company

Phase 2 Terminated
29 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03035006 2018-11-06

Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Taiwan Liposome Company

Phase 1/2 Terminated
1 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01425996 2018-08-21

A Dose-escalation Study of LipotecanĀ® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma

Taiwan Liposome Company

Phase 1/2 Terminated
3 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚔